REGENERON PHARMACEUTICALS, INC. (REGN) Total liabilities 2016–2025
REGENERON PHARMACEUTICALS, INC. (REGN) total liabilities at each fiscal year-end, per SEC filings.
$9.3BFY2025 · since FY2016: $2.5B → $9.3B
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $9.3B | +10.7% |
| FY2024 | $8.4B | +18.3% |
| FY2023 | $7.1B | +8.5% |
| FY2022 | $6.6B | -1.7% |
| FY2021 | $6.7B | +8.6% |
| FY2020 | $6.1B | +65.2% |
| FY2019 | $3.7B | +24.8% |
| FY2018 | $3.0B | +13.6% |
| FY2017 | $2.6B | +3.8% |
| FY2016 | $2.5B | — |
Years the filer does not tag total liabilities directly are shown as reported total assets − reported shareholders’ equity at the same fiscal year-end.
Source: SEC XBRL filings · For reference only · Not investment advice